Global Closed Blood Sampling Systems Market Size By Type (One Handed, Two Handling), By Application (Hospitals and Surgical Clinics, Diagnostic Centers), By Region, And Segment Forecasts, 2023 to 2032

The Global Closed Blood Sampling Systems Market was valued at USD 630 million in 2023 and is expected to reach USD 1.12 billion by 2031, growing at a CAGR of 7.6% during the forecast period (2023–2031). The market is being driven by the increasing emphasis on infection control in hospitals, rising incidences of chronic and infectious diseases, and the growing demand for safer and more efficient blood sampling techniques. Closed blood sampling systems significantly reduce the risk of contamination and bloodborne pathogen exposure, making them a vital component in intensive care and surgical units worldwide.

Drivers:

Infection Prevention & Safety Standards:

Healthcare systems globally are adopting closed blood sampling systems to reduce iatrogenic blood loss and improve infection control. These systems minimize the need for open needle transfers, significantly lowering the risk of hospital-acquired infections (HAIs).

Growing ICU & Critical Care Demand:

Rising demand for intensive and critical care, especially after the COVID-19 pandemic, has accelerated the need for safe, reliable, and contamination-free blood sampling devices in hospitals and clinics.

Increasing Burden of Chronic Conditions:

A rise in diabetes, cancer, renal diseases, and cardiovascular conditions requiring frequent blood tests is spurring demand for advanced blood sampling systems, particularly in inpatient settings.

Restraints:

High Initial Cost:

Closed blood sampling systems generally have higher upfront costs than traditional methods, limiting their adoption in low-income or cost-sensitive healthcare facilities.

Limited Awareness in Developing Countries:

Despite their benefits, closed systems remain underutilized in several emerging markets due to a lack of awareness, limited access, and lower health spending.

Opportunity:

Shift Toward Safer Hospital Practices:

With a global push toward safer patient handling protocols, demand for advanced blood sampling systems is set to surge. Hospitals are prioritizing solutions that improve both patient and staff safety.

Emerging Markets Expansion:

Healthcare infrastructure improvement in regions like Asia-Pacific, Latin America, and parts of Africa presents new opportunities for manufacturers to expand the adoption of closed blood sampling systems.

Market by System Type Insights:

The Manual Closed Blood Sampling Systems segment dominated in 2023, owing to its wide use in ICUs and general wards due to affordability and ease of training. However, the Automated Closed Blood Sampling Systems segment is projected to grow faster during the forecast period as hospitals invest in automation to enhance efficiency and safety.

Market by End-use Insights:

In terms of end-use, Hospitals accounted for the largest share in 2023, contributing to over 55% of total revenue. Their dominance stems from the high volume of inpatient care and frequent blood sampling needs in critical care units. Diagnostic laboratories are also experiencing robust growth due to the rising demand for high-throughput and error-free sample collection methods.

Market by Regional Insights:

North America led the global closed blood sampling systems market in 2023, attributed to strong healthcare infrastructure, early adoption of advanced medical devices, and strict regulations promoting infection control. The Asia-Pacific region is projected to witness the fastest CAGR, driven by rising healthcare investments, a large patient population, and increased focus on reducing HAIs.

Competitive Scenario:

Key players in the global closed blood sampling systems market include BD (Becton, Dickinson and Company), Smiths Medical, ICU Medical, Inc., Merit Medical Systems, Fresenius Kabi, and Terumo Corporation. These companies are prioritizing innovation, partnerships, and market expansion. For instance:

In 2024, BD launched a next-generation closed blood collection system with an integrated safety shield for improved needle stick injury prevention.

In 2023, ICU Medical expanded its vascular access product line with enhanced blood sampling safety features.

In 2022, Merit Medical entered strategic collaborations to introduce its closed system to emerging markets in Southeast Asia.

Scope of Work – Global Closed Blood Sampling Systems Market

Report Metric Details

Market Size (2023) USD 630 million

Projected Market Size (2031) USD 1.12 billion

CAGR (2023–2031) 7.6%

Key Segments By System Type, By End-use, By Region

Growth Drivers Infection control focus, ICU demand

Opportunities Emerging market expansion, automation

Key Market Developments:

March 2024: Smiths Medical launched a redesigned manual closed blood sampling system to enhance workflow efficiency in ICUs.

October 2023: BD announced a partnership with a European hospital chain to deploy its advanced closed sampling systems in all intensive care units.

June 2023: Fresenius Kabi expanded its R&D center to accelerate innovations in blood collection and infusion safety.

FAQs:

1) What is the current market size of the Global Closed Blood Sampling Systems Market?

The market was valued at USD 630 million in 2023.

2) What is the major growth driver of the Global Closed Blood Sampling Systems Market?

The major growth driver is the increasing demand for infection control and safety in hospital environments.

3) Which is the largest region during the forecast period in the Global Closed Blood Sampling Systems Market?

North America is expected to remain the largest regional market due to its advanced healthcare system and early technology adoption.

4) Which segment accounted for the largest market share in the Global Closed Blood Sampling Systems Market?

The Hospitals segment held the largest market share in 2023.

5) Who are the key market players in the Global Closed Blood Sampling Systems Market?

Key players include BD, Smiths Medical, ICU Medical, Merit Medical Systems, Fresenius Kabi, and Terumo Corporation.